Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Change in Accured Expenses (2023 - 2024)

Sagimet Biosciences has reported Change in Accured Expenses over the past 2 years, most recently at $444000.0 for Q4 2024.

  • Quarterly results put Change in Accured Expenses at $444000.0 for Q4 2024, up 38.75% from a year ago — trailing twelve months through Dec 2024 was -$907000.0 (down 855.83% YoY), and the annual figure for FY2025 was $929000.0, up 202.43%.
  • Change in Accured Expenses for Q4 2024 was $444000.0 at Sagimet Biosciences, up from -$1.7 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for SGMT hit a ceiling of $1.4 million in Q3 2023 and a floor of -$1.7 million in Q3 2024.